Details for Patent: 6,331,550

Title:	Methods of use of quinolone compounds against anaerobic pathogenic bacteria
Abstract:	This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.
Inventor(s):	Citron; Diane M. (Santa Monica, CA), Goldstein; Ellie J. C. (Santa Monica, CA)
Assignee:	SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:	Sep 21, 1999
Application Number:	09/400,144
Claims:	1. A method for modulating metabolism of anaerobic pathogenic bacteria comprising the step of contacting anaerobic pathogenic bacteria with an antibacterially effective amount of a composition comprising a gemifloxacin compound, or antibacterially effective derivatives thereof. 2. The method of claim 1 wherein said bacteria is selected from the group consisting of: a member of the genus Peptostreptococci, a member of the genus Actinomyces, a member of the genus Clostridium, a member of the genus Anaerobiospirillum, a member of the genus Fusobacterium, and a member of the genus Bilophila. 3. The method of claim 1 wherein said modulating metabolism is inhibiting growth of said bacteria. 4. The method of claim 1 wherein said modulating metabolism is killing said bacteria. 5. The method of claim 1 wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal. 6. The method of claim 5 wherein said mammal is a human. 7. The method of claim 1 wherein said bacteria is selected from the group consisting of: Peptostreptococci asaccharolyticus, Peptostreptococci magnus, Peptostreptococci micros, Peptostreptococci prevotii, Porphyromonas asaccharolytica, a Porphyromonas canoris, Porphyromonas gingivalis, Porphyromonas macaccae, Actinomyces israelii, Actinomyces odontolyticus, Clostridium innocuum, Clostridium clostridioforme, Clostridium difficile, Bacteroides tectum, Bacteroides ureolyticus, Bacteroides gracilis (Campylobacter gracilis), Prevotella intermedia, Prevotella heparinolytica, Prevotella oris-buccae, Prevotella bivia, Prevotella melaninogenica, Fusobacterium naviforme, Fusobacterium necrophorum, Fusobacterium varium, Fusobacterium ulcerans, Fusobacterium russii, and Bilophila wadsworthia. 8. The method according to claim 1 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof. 9. The method according to claim 8 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof. 10. The method according to claim 9 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate. 11. The method according to claim 2 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof. 12. The method according to claim 7 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof. 13. The method according to claim 11 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof. 14. The method according to claim 12 wherein the gemifloxacin compound is gemifloxacin mesylate or hydrate thereof. 15. The method according to claim 13 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate. 16. The method according to claim 14 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.